Core Viewpoint - Lepu Biopharma-B (02157) experienced a significant increase in stock price, rising by 7.34% to HKD 6.87, with a trading volume of HKD 13.97 million following the approval of its drug Meiyouheng (injectable Vebrecatinib) by the National Medical Products Administration in China [1] Group 1 - The National Medical Products Administration has approved Meiyouheng (injectable Vebrecatinib) for market entry in China, marking it as the first approved EGFR-targeted antibody-drug conjugate (ADC) in the country [1] - Meiyouheng is designed for the treatment of recurrent or metastatic nasopharyngeal carcinoma (R/M NPC), representing a significant advancement in targeted cancer therapy [1] - The approval of Meiyouheng is considered a major milestone for the company, enhancing treatment efficacy for patients and paving the way for the expansion of its indications and commercial potential [1]
乐普生物-B高开逾7% 注射用维贝柯妥塔单抗国内获批上市